Fusion’s interim (March to September) FY22 results confirmed good operational progress with revenues up by 20% to £2.3m on an underlying basis. Reported sales were higher at £2.4m, up by 28%, boosted by a £150k milestone, Fusion’s first such, received from the progression of a 2018 vintage project towards trials. We consider the growth in sales to be impressive considering marketing activities will have been conducted entirely virtually, rather than at traditional in-person conferences/shows. Op ....
07 Dec 2021
Strong growth in uncertain times
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong growth in uncertain times
Fusion Antibodies Plc (FAB:LON) | 3.8 0 0.0% | Mkt Cap: 3.58m
- Published:
07 Dec 2021 -
Author:
Robin Davison -
Pages:
3
Fusion’s interim (March to September) FY22 results confirmed good operational progress with revenues up by 20% to £2.3m on an underlying basis. Reported sales were higher at £2.4m, up by 28%, boosted by a £150k milestone, Fusion’s first such, received from the progression of a 2018 vintage project towards trials. We consider the growth in sales to be impressive considering marketing activities will have been conducted entirely virtually, rather than at traditional in-person conferences/shows. Op ....